Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross-Sectional Study of Rehabilitation Training Intensity and Physical Restraints in Patients With Cardiovascular Disease and Neurocognitive Disorders in Acute Care Hospitals.

Cureus·2026
Same author

Corrigendum to "Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of the Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2019-2020: General view of the pathogens' antibacterial susceptibility" [J. Infect. Chemother. 29 (2023) 731-743].

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2026
Same author

Genomic analysis of dental pulp mesenchymal stromal cells for therapeutic applications.

Regenerative therapy·2026
Same author

Validity and reliability of the Japanese Adult Social Care Outcomes Toolkit four-level Self Completion Tool (ASCOT SCT4) in community mental health service users in Japan.

Health and quality of life outcomes·2026
Same author

Automatic detection and measurement system for aortic aneurysms using deep learning-based artificial intelligence.

The international journal of cardiovascular imaging·2026
Same author

Intraoperative completion study using three-dimensional computed tomography angiography in carotid endarterectomy surgery: Technical case series.

Neurosurgical review·2026

Related Experiment Video

Updated: Jun 15, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

The development of a knowledge base for basic active structures: an example case of dopamine agonists.

Takashi Okada1, Masumi Yamakawa, Norihito Ohmori

  • 1Department of Informatics, School of Science & Technology, Kwansei Gakuin University, Sanda, Hyogo, Japan. okada-office@kwansei.ac.jp

Chemistry Central Journal
|February 26, 2010
PubMed
Summary

This study introduces BASiC, a knowledge base for identifying basic active structures (BASs) in chemical compounds. This aids drug design by systematically extracting and interpreting these key substructures for various bioactivities.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Primary Culture of Mouse Dopaminergic Neurons
11:58

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

Related Experiment Videos

Last Updated: Jun 15, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Primary Culture of Mouse Dopaminergic Neurons
11:58

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

Area of Science:

  • Medicinal Chemistry
  • Cheminformatics

Background:

  • Chemical compounds with similar bioactivity often share characteristic substructures, termed basic active structures (BASs).
  • Extracting BASs from diverse compound databases presents a significant challenge.
  • Data mining and chemical expertise enable systematic BAS elaboration.

Purpose of the Study:

  • To present BASiC, a novel knowledge base for basic active structures.
  • To demonstrate the process of BAS extraction using dopamine agonists as examples.

Main Methods:

  • Development of a comprehensive BAS knowledge base (BASiC).
  • Application of data mining techniques for BAS extraction.
  • Interpretation of extracted BASs using proposed template structures.

Main Results:

  • The BASiC knowledge base currently covers 46 distinct bioactivities.
  • Successful extraction and interpretation of BASs for dopamine agonists (D1, D2, Dauto).
  • Validation of BAS extraction through proposed template structures.

Conclusions:

  • The BASiC knowledge base serves as a valuable tool for drug design.
  • Identified BASs and supporting structures can guide the development of new template structures.
  • Facilitates the design of novel lead compounds through rational interpretation of active structures.